Lorem targeted quia curatio SARCOMA
Aliena sane non cancer, non multum de notitia SARCOMA. In facto, SARCOMA, quod est genus cancer est saepe neglecta a populo. Et hoc genus cancer apparet in cutis et in periosteum, et est satis equivalent invenire quod conditio gravescit Celeriter, cessum SARCOMA-targeting medicinae potest patitur aegris, ut respirare possit stabiliendum corpora morbo in a brevis cursum temporis, et metastasis ne et gravi situ, redactam periculo minas ad vitam aegris.
Targeted medicamento pro sarcoma
Bevacizumab, pazopanib, sunitinib, etc. sunt medicamenta sarcoma-scopa, sed hoc non omni aegro aptum est. Praevia est experimentum geneticae facere. Si mutatio generum est mutationis KRAS, inhibitores MEK adhiberi possunt, si est mutatio PIK3CA, BKM120, mTOR inhibitor, etc. Si EGFR mutatio est, medicamentum TIKi adhiberi potest. Medicamenta iaculata adhuc ideas habent, sed clavis est ad unguem scire quid sit mutatio genetica, quae auxilium technologiae secundae generationis sequelae technologiarum requirit propter frequentiam mutationum geneticarum in KRAS, PIK3CA, EGFR et MET usque ad 100% non addit. . Si condiciones permittunt, AVASTIN coniunctim etiam cum chemotherapy adhiberi possunt.
Quae sunt sarcoma-targeting medicinae?
1.Bevacizumab
Bevacizumab, a human recombinant VEGF antibody, has been shown to have clinical efficacy in combination regimens in rectal cancer and other malignancies. Agulnik et al. Conducted a multi-center prospective, phase II clinical trial to evaluate the safety and effectiveness of the single-agent bevacizumab, including 30 patients with advanced STS, including 23 cases of angiosarcoma and 7 cases of epithelioid hemangioendothelioma. Monotherapy was well tolerated, partial response (PR), 2 cases, stable disease (SD), 15 cases. After two cycles of treatment, the median progression-free survival (PFS) was 12 weeks, and the overall survival (OS) was 52.7 weeks. This test shows that bevacizumab is safe and effective in patients with angiosarcoma and epithelioid hemangioendothelioma.
2.Pazopanib
Pazopanib est oralis multi-iaculatus inhibitor tyrosini kinasi receptantis moleculae parvae, et est primum medicamentum iaculi probatum a FDA per decades ad tractandum sarcoma mollia textus provecta (non-liposarcoma). Pazopanib est auctum endotheliale vascularium receptor VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α et -β, FGFR-1 et -3, cytokinus receptor (Kit), interleukin-2 receptor receptor inhibitor tyrosinus kinasus. T cellam kinasam (Itk), leukocyto-specificam interdum tyrosinum kinasum (Lck), et glycoprotein transmembranum receptorem tyrosinum kinasum (c-Fms). FDA approbat pazopanib pro patientibus sarcoma.
3.Sunitinib
Sunitinib is an oral small molecule receptor tyrosine kinase inhibitor with multiple effects of inhibiting tuberculum angiogenesis and anti-tumor cell growth. Targets for the drug to exert anti-cancer effects include: PDGFR-α and -β, VEGFR1, VEGFR2, VEGFR3, FLT-3, CSF-1R, kit and ret. Sunitide has multiple effector pathways, making it a reliable anti-tumor targeted drug for non-GIST sarcomas, with two phase II clinical trials evaluating its safety and effectiveness.
4.Sorafinib
Sorafenib inhibitor multikinase oralis est. Variis simul inhibere potest kinases superficiei intracellulares et cellulas, inclusas BRAF kinasas, VEGFR-2, VEGFR-III, PDGFR-β, KIT, et FMS sicut tyrosinum kinasum III (FLT-3).
5.Cediranib
Sildenib, factor incrementi endothelialis vascularium receptor inhibitor tyrosinus kinasus, Kummar et al. Inventum per periodum II clinicae cognitionis quae bonam efficaciam ostendit ad sarcoma metastatica acinaris mollis, 35% aegroti PR, SD in 60% aegrorum facta sunt, et altiore morbo moderatio 84% ad 24 septimanas pervenit.
6. Anlotinib
Anlotinib est receptor multi- clypei tyrosini kinasi (RTK) inhibitoris qui scuta incrementi endothelialis vascularium receptaculum (VEGFR1 / 2/3) et factor incrementi fibroblast receptor (FGFR1 / 2/3) scuta qualia ut factores receptores incrementi in platelet derivatos (PDGFRα / β), c.-Rit, et Rel. Nuper investigationis in therapiis tumore-scopatis usum suum continuavit.
